Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Roze

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Diabetes & Metabolism|March 9, 2006
Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetesA J Palmer, R Chen, W J Valentine, et al.
Advances in Therapy|June 15, 2007
Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United StatesWilliam J Valentine, K M Erny-Albrecht, J A Ray, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|March 17, 2022
Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring system in people with type 1 diabetes in AustraliaJ J Isitt, S Roze, D Tilden, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]L Turner, M E Velard, C Loveman, et al.
Diabetes, Obesity & Metabolism|January 4, 2007
Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the USJ A Ray, W J Valentine, S Roze, et al.
Journal of Medical Economics|March 18, 2016
Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the NetherlandsS Roze, E Duteil, J Smith-Palmer, et al.
International Journal of Clinical Practice|May 16, 2008
Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish settingG Goodall, J H Jendle, W J Valentine, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Diabetes & Metabolism|March 9, 2006
Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetesA J Palmer, R Chen, W J Valentine, et al.
Advances in Therapy|June 15, 2007
Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United StatesWilliam J Valentine, K M Erny-Albrecht, J A Ray, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|March 17, 2022
Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring system in people with type 1 diabetes in AustraliaJ J Isitt, S Roze, D Tilden, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]L Turner, M E Velard, C Loveman, et al.
Diabetes, Obesity & Metabolism|January 4, 2007
Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the USJ A Ray, W J Valentine, S Roze, et al.
Journal of Medical Economics|March 18, 2016
Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the NetherlandsS Roze, E Duteil, J Smith-Palmer, et al.
International Journal of Clinical Practice|May 16, 2008
Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish settingG Goodall, J H Jendle, W J Valentine, et al.
Pageof 3